Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Equity Ratio (2021 - 2023)

Historic Equity Ratio for ADC Therapeutics (ADCT) over the last 3 years, with Q3 2023 value amounting to 118.44.

  • ADC Therapeutics' Equity Ratio fell 910.71% to 118.44 in Q3 2023 from the same period last year, while for Sep 2023 it was 118.44, marking a year-over-year decrease of 910.71%. This contributed to the annual value of 0.16 for FY2022, which is 9990.59% down from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Equity Ratio is 118.44, which was down 910.71% from 114.34 recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Equity Ratio peaked at 143.44 during Q2 2022, and registered a low of 0.0 during Q3 2021.
  • Moreover, its 3-year median value for Equity Ratio was 114.34 (2023), whereas its average is 70.37.
  • Over the last 5 years, ADC Therapeutics' Equity Ratio had its largest YoY gain of 9257629566.28% in 2022, and its largest YoY loss of 3337.06% in 2022.
  • Over the past 3 years, ADC Therapeutics' Equity Ratio (Quarter) stood at 0.24 in 2021, then crashed by 33.37% to 0.16 in 2022, then surged by 73071.67% to 118.44 in 2023.
  • Its last three reported values are 118.44 in Q3 2023, 114.34 for Q2 2023, and 129.76 during Q1 2023.